Reversal of neuronal tau pathology, metabolic dysfunction, and electrophysiological defects via adiponectin pathway-dependent AMPK activation.
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1076573 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR27969100_1.fastq.gz | Fastqsanger.gz | |||
| SRR27969100_2.fastq.gz | Fastqsanger.gz | |||
| SRR27969101_1.fastq.gz | Fastqsanger.gz | |||
| SRR27969101_2.fastq.gz | Fastqsanger.gz | |||
| SRR27969102_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 252 |
Similar Datasets
Project description:Changes in brain mitochondrial metabolism are coincident with functional decline; however, direct links between the two have not been established. Here, we show that mitochondrial targeting via the adiponectin receptor activator AdipoRon (AR) clears neurofibrillary tangles (NFTs) and rescues neuronal tauopathy-associated defects. AR reduced levels of phospho-tau and lowered NFT burden by a mechanism involving the energy-sensing kinase AMPK and the growth-sensing kinase GSK3b. The transcriptional response to AR included broad metabolic and functional pathways. Induction of lysosomal pathways involved activation of LC3 and p62, and restoration of neuronal outgrowth required the stress-responsive kinase JNK. Negative consequences of NFTs on mitochondrial activity, ATP production, and lipid stores were corrected. Defects in electrophysiological measures (e.g., resting potential, resistance, spiking profiles) were also corrected. These findings reveal a network linking mitochondrial function, cellular maintenance processes, and electrical aspects of neuronal function that can be targeted via adiponectin receptor activation.
2024-12-09 | GSE255813 | GEO
Project description:Adipose tissue is a metabolic and endocrine organ that secretes numerous bioactive molecules called adipocytokines. Among these, adiponectin has been argued to have a crucial role in obesity-associated breast cancer. The key molecule of adiponectin signaling is AMP-activated protein kinase (AMPK), mainly activated by Liver Kinase B1 (LKB1). Here, we demonstrated how the ERalfa/LKB1 interaction may negatively interfere with the capability of LKB1 to phosphorylate AMPK and then inhibit its downstream signaling TSC2/mTOR/p70S6k. In MCF-7 cells upon adiponectin AMPK signaling was not working, keeping its downstream protein Acetyl-CoA Carboxylase (ACC) still active. In contrast, in MDA-MB-231 cells the phosphorylation of AMPK and ACC was enhanced with consequent inhibition of both lipogenesis and cell growth. Thus, upon adiponectin, ERalfa signaling switched the energy balance of breast cancer cells towards a lipogenic phenotype. In other words, adiponectin in all the concentrations tested played an inhibitory role on ERalpha-negative breast cancer cell growth and progression either in vitro or in vivo. In contrast, low adiponectin levels, similar to those circulating in obese patients, worked on ERalfa-positive cells as a growth factor, stimulating their growth and progression. The latter effect seems to be blunted in vivo only in the presence of high adiponectin concentration. Based on the present results, it can be concluded that if we prospectively address adiponectin as a pharmacological tool, a separate therapeutic treatment should be carefully assessed in ERalfa-positive and negative breast-cancer patients.
2020-02-27 | E-MTAB-6120 | biostudies-arrayexpress
Project description:The microtubule-associated protein Tau is a driver of neuronal dysfunction in Alzheimer’s disease and numerous other tauopathies. In this process, Tau initially undergoes subtle changes to its abundance, subcellular localization and a vast array of post-translational modifications, including phosphorylation, that progressively result in the protein’s aggregation and dysregulation of multiple Tau-dependent cellular processes. Given the various loss- and gain-of-functions of Tau in disease and the brain-wide changes in the proteome that characterize tauopathies, we asked targeting Tau would restore the proteomic dyshomeostasis observed in disease. To this end, we generated a novel pan-Tau antibody, RNJ1, that preferentially binds human Tau and neutralizes proteopathic seeding activity in multiple cell-lines, and benchmarked it against a clinically tested pan-Tau antibody, HJ8.5 (murine version of tilavonemab). We next evaluated both antibodies, alone and in combination, in the K3 mouse model of tauopathy, showing reduced Tau pathology and improved neuronal functions, without obtaining synergistic effects for the combination treatment. Quantitative proteomics revealed deregulation of metabolic and microtubule-associated proteins in K3 compared to wild-type brain, strengthening previously reported findings of functional defects in multiple tauopathy models. Importantly, both treatments, in particular RNJ1, reversed protein and phospho-protein dyshomeostasis for both increased and decreased proteins in the K3 brain, shifting levels towards those observed in wild-type mice. Gene set over-representation analysis further confirmed that proteins undergoing restoration are involved in biological pathways affected in K3 mice. Together, our study suggests that a Tau immunotherapy-induced reversal of proteomic dyshomeostasis links target engagement and treatment efficacy.
2025-05-06 | PXD045799 | Pride
Project description:Uncoupling effects of ERalfa on LKB1/AMPK interaction upon adiponectin exposure in breast cancer
| PRJEB36821 | ENA
Project description:Transcriptionnal profiling of 4 human cell lines treated during 3 hours with human adiponectin Keywords: transcriptionnal analysis Four human cell lines (Hela, HepG2, Panc-1, Hek293) were grown until confluence. These cell lines were serum depleted during 2 hours and then treated with human adiponectin (2,5 µg/ml) during 3 hours. Each adiponectin stimulated cell line was compared to depleted cell line. Depleted cell line was considered as control.
2010-12-09 | E-GEOD-14070 | biostudies-arrayexpress
Project description:Obese women who develop gestational diabetes show lower adiponectin levels across pregnancy than obese euglycemic women suggesting that obese women with low adiponectin levels have an impaired capacity to handle the metabolic changes during pregnancy. Adiponectin acts on the placenta during pregnancy; this fact allows for the interesting possibility that adiponectin can exert endocrine effects on the developing fetus. The aim was to investigate how adiponectin affects fetal growth, placenta function and metabolic functions during pregnancy. Wild-type (wt) and adiponectin transgenic (APNtg) mice were fed normal chow or a high fat/high sucrose (HF/HS) diet for 8 weeks before mating. Dams and fetuses were dissected at gestational day 18.5. Maternal adiponectin overexpression decreased fetal body weight in dams on normal chow, and even more in dams on HF/HS diet. Pools of two placentas or two livers from one male and one female fetus with the same genotype (wt or APNtg) from the same dam on HF/HS diet were used in proteomic analysis, and a total of five pools per group (wt-wt, wt-APNtg, APNtg-wt, APNtg-APNtg) were included in the liquid chromatography-tandem mass spectrometry (LS-MS/MS) analysis. In total, 7290 proteins were identified in placenta, and 7301 proteins in fetal liver. Next, we analyzed phosphosites, in total,19264 sites were identified in placenta proteins and 15334 sites were identified in fetal liver proteins. We then applied pathway analysis to the total protein and phosphopeptide data using PRISM and Enrichr.
2025-04-23 | PXD025390 | Pride
Project description:The physiological role of the spliced form of X-box-binding protein 1 (XBP1s), a key transcription factor of the endoplasmic reticulum (ER) stress response, in adipose tissue remains largely unknown. Here we show that overexpression of XBP1s promotes adiponectin multimerization in adipocytes, thereby regulating systemic glucose homeostasis. Ectopic expression of XBP1s in adipocytes improves glucose tolerance and insulin sensitivity in both lean and obese (ob/ob) mice. The beneficial effect of adipocyte XBP1s on glucose homeostasis is associated with elevated serum levels of HMW adiponectin and indeed, is adiponectin dependent. Mechanistically, XBP1s promotes adiponectin multimerization rather than activating its transcription likely through a direct regulation of the expression of several ER-chaperones involved in adiponectin maturation, including Grp78, Pdia6, ERp44 and DsbA-L. Thus, we conclude that XBP1s is an important regulator of adiponectin multimerization, which may lead to a new therapeutic approach for the treatment of type 2 diabetes and hypoadiponectinemia. Epididymal adipose tissue from wild type and XBP1-overexpressing mice was subjected to gene expression profiling.
2013-11-21 | E-GEOD-36031 | biostudies-arrayexpress
Project description:Bone marrow derived macrophages (BMDM) generated from c57bl/6j mice bone marrow cells were stimulated for 18 h with 12 microgram/ml adiponectin, RNA from non-stimulated or 18 h adiponectin-stimulated BMDM subjected to a agilent microarray analysis Three different non-stimulated and 3 different 18 h adiponectin (12 microgram/ml) RNA samples were subjected to a micrrorray analysis
2014-07-03 | E-GEOD-49332 | biostudies-arrayexpress
Project description:Signaling between mammalian adiponectin and a mosquito adiponectin receptor reduces Plasmodium transmission
| PRJNA817525 | ENA
Project description:The adipocyte-derived hormone adiponectin potently inhibits osteoclast formation in vitro. Gene expression profiling of murine bone marrow cells treated with adiponectin was used to identify candidate genes that mediate the effect of adiponectin to inhibit osteoclastogenesis in these cultures. However, we found that contamination by lipopolysaccharide confounds the study of adiponectin activity. Bone marrow cells were cultured for up to five days and RNA was extratced from cells treated with adiponectin and from untreated controls at different time points.
2012-02-02 | E-GEOD-35466 | biostudies-arrayexpress